0001415889-24-001756.txt : 20240124 0001415889-24-001756.hdr.sgml : 20240124 20240124164130 ACCESSION NUMBER: 0001415889-24-001756 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240122 FILED AS OF DATE: 20240124 DATE AS OF CHANGE: 20240124 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Duraibabu Prathyusha CENTRAL INDEX KEY: 0001779092 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-30171 FILM NUMBER: 24556986 MAIL ADDRESS: STREET 1: C/O SANGAMO THERAPEUTICS, INC. STREET 2: 501 CANAL BLVD. CITY: RICHMOND STATE: CA ZIP: 94804 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SANGAMO THERAPEUTICS, INC CENTRAL INDEX KEY: 0001001233 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 680359556 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 501 CANAL BLVD. CITY: RICHMOND STATE: CA ZIP: 94084 BUSINESS PHONE: 5109706000 MAIL ADDRESS: STREET 1: 501 CANAL BLVD. CITY: RICHMOND STATE: CA ZIP: 94084 FORMER COMPANY: FORMER CONFORMED NAME: SANGAMO BIOSCIENCES INC DATE OF NAME CHANGE: 20000208 4 1 form4-01242024_090116.xml X0508 4 2024-01-22 0001001233 SANGAMO THERAPEUTICS, INC SGMO 0001779092 Duraibabu Prathyusha C/O SANGAMO THERAPEUTICS, INC. 501 CANAL BLVD. RICHMOND CA 94084 false true false false SVP, CHIEF FINANCIAL OFFICER 0 Common Stock 2024-01-22 4 A 0 712500 0 A 843505 D Represents shares of common stock issuable upon settlement of a restricted stock unit ("RSU") grant that will vest as to one-half (1/2) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 4 successive equal quarterly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP")) through each such date and subject to acceleration in full in the event of a Change in Control (as defined in the 2018 EIP). Includes: (a) 4,584 shares subject to the Reporting Person's February 25, 2021 RSU grant that will vest in one final installment on February 25, 2024, (b) 19,219 shares subject to the Reporting Person's February 25, 2022 RSU grant that will vest in successive equal quarterly installments through February 25, 2025, (c) 53,438 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest as to one-quarter (1/4) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter and (d) 2,500 shares subject to Reporting Person's June 11, 2021 RSU grant that will vest in one final installment on June 11, 2024. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. /s/ Ron A. Metzger, Attorney-in-Fact 2024-01-24